Incyte (Nasdaq: INCY) has agreed to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of San Francisco-based Star Therapeutics, LLC, for USD 1.25 billion upfront, with up to USD 750 million in additional sales-based milestone payments, bringing total potential consideration to USD 2.0 billion. The Wilmington, Delaware-based company is acquiring Vega to add VGA039, an investigational monoclonal antibody in Phase III development for von Willebrand disease (VWD), to its hematology portfolio.
Under the terms of the stock purchase agreement, Incyte will acquire all outstanding shares of Vega Therapeutics. The USD 1.25 billion upfront payment is structured as an equity acquisition and is expected to generate an R&D charge of approximately USD 1.25 billion in Incyte's Q3 2026 GAAP and non-GAAP results. The USD 750 million in contingent payments are tied exclusively to sales milestones; no development or regulatory milestone tranches were disclosed. The transaction has been approved by both boards and is expected to close in Q3 2026, subject to expiration of the Hart-Scott-Rodino waiting period and other customary conditions.
VGA039 targets Protein S, a vitamin K-dependent plasma glycoprotein that normally suppresses coagulation, through a dual mechanism: promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. By modulating Protein S rather than directly replacing deficient von Willebrand factor, VGA039 operates independently of VWD subtype, giving it potential utility across all forms of the disease. The candidate has received Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations from the US FDA. It has advanced into the Phase III VIVID-6 study (NCT07115004), a global, single-arm crossover trial evaluating subcutaneous VGA039 as prophylaxis across all VWD types. If approved, VGA039 would be the first subcutaneously self-administered, once-monthly prophylactic option for VWD patients who currently depend on two to three intravenous infusions per week of factor replacement therapies.
The deal's premium reflects both the asset's clinical stage and the scarcity of late-stage, mechanism-differentiated programs in inherited bleeding disorders. In a structurally comparable transaction, BioCryst Pharmaceuticals acquired Astria Therapeutics for approximately USD 700 million to secure navenibart, a Phase III monoclonal antibody targeting plasma kallikrein for hereditary angioedema prophylaxis — another rare, inherited disorder where subcutaneous antibody dosing represents a meaningful advance over existing standard of care. Incyte's USD 1.25 billion upfront payment for a comparable development-stage asset in a similarly sized orphan population indicates a higher valuation premium, potentially reflecting VGA039's Breakthrough Therapy designation and its potential pan-VWD applicability. In the same disease area, Hemab Therapeutics raised USD 346.7 million via a Nasdaq IPO to advance HMB-002, a monovalent subcutaneous antibody in Phase I/II for VWD.